Indeed, the estimated 20-year risks of developing contralateral breast cancer in this study were higher compared to a previously published study with a prospective design:1 47% versus 40% for BRCA1 heterozygotes and 40% versus 26% for BRCA2 heterozygotes, respectively. The gene discussed is BRCA1; the disease is breast cancer.